Newamsterdam Pharma Company N.V. (NAMS)
NASDAQ:NAMS
Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$34.68
-$0.03(-0.12%)
At close: 4:00 PM EST
$34.68
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$17.63 - $42.21
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.54M
Market Cap
$3.43B
Enterprise Value$3.48B
Total Cash (Recent Filing)$636.11M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Aug 12, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume1,373,949
30 Day Avg. Volume1,539,695
Financial Highlights & Ratios
PEG Ratio0.62
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue154.21
Enterprise Value/Gross Profit158.13
Enterprise Value/Ebitda-15.01
Forecast
1Y Price Target
$47.86Price Target Upside38.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.83
Revenue Forecast (FY)$29.28M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt against a large equity base reduces refinancing and solvency risk, giving management durable financial flexibility to fund clinical programs and respond to setbacks. This strong capital structure supports R&D runway and limits disruption risk over the next several months.
Very High Gross MarginReported gross margin of ~97.5% reflects scalable product economics typical for pharmaceuticals. If obicetrapib reaches commercialization, low incremental COGS could enable substantial margin expansion, helping convert future revenue into operating leverage and lasting profitability.
Governance & Capital FlexibilityShareholder approval of an ESPP and extended share-issuance authority provides structural benefits: equity incentives improve employee retention and alignment, while formal capital-raising flexibility enables timely financing or partnerships to support trials and launches without protracted governance delays.
Bears Say
High Cash BurnA sustained cash burn of roughly -$142M TTM will deplete reserves absent financing, forcing capital raises or partnerships. That ongoing drain raises dilution risk, constrains funding flexibility for expensive clinical programs, and is a durable operational vulnerability until revenue scales.
Deep UnprofitabilityNet margin near -943% and negative returns on equity indicate structural unprofitability. Even material revenue gains would need to overcome very large fixed costs and accumulated losses; reversing this trend requires successful regulatory approval and commercial execution to achieve sustainable earnings.
Small, Volatile Revenue BaseTTM revenue of $22.6M, described as volatile and below prior levels, provides limited coverage of R&D and SG&A. This limited and uneven top-line makes planning and funding late-stage trials harder and leaves the business reliant on external financing or milestone events for survival.
NewAmsterdam Pharma Company News
NAMS FAQ
What was Newamsterdam Pharma Company N.V.’s price range in the past 12 months?
Newamsterdam Pharma Company N.V. lowest stock price was $17.63 and its highest was $42.20 in the past 12 months.
What is Newamsterdam Pharma Company N.V.’s market cap?
Newamsterdam Pharma Company N.V.’s market cap is $3.43B.
When is Newamsterdam Pharma Company N.V.’s upcoming earnings report date?
Newamsterdam Pharma Company N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 62 days.
How were Newamsterdam Pharma Company N.V.’s earnings last quarter?
Newamsterdam Pharma Company N.V. released its earnings results on May 07, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.059.
Is Newamsterdam Pharma Company N.V. overvalued?
According to Wall Street analysts Newamsterdam Pharma Company N.V.’s price is currently Undervalued.
Does Newamsterdam Pharma Company N.V. pay dividends?
Newamsterdam Pharma Company N.V. does not currently pay dividends.
What is Newamsterdam Pharma Company N.V.’s EPS estimate?
Newamsterdam Pharma Company N.V.’s EPS estimate is -0.48.
How many shares outstanding does Newamsterdam Pharma Company N.V. have?
Newamsterdam Pharma Company N.V. has 116,903,980 shares outstanding.
What happened to Newamsterdam Pharma Company N.V.’s price movement after its last earnings report?
Newamsterdam Pharma Company N.V. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 12.456%.
Which hedge fund is a major shareholder of Newamsterdam Pharma Company N.V.?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.86 (38.00% Upside)
$47.86 (38.00% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 386.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $13.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.69%
12-Months-Change
Fundamentals
Return on Equity
-29.80%
Trailing 12-Months
Asset Growth
-10.48%
Trailing 12-Months
Company Description
Newamsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V. functions as a clinical-phase biopharmaceutical enterprise, dedicated to enhancing treatment outcomes for patients dealing with metabolic disorders. The company's principal experimental medication, obicetrapib, represents a pioneering and targeted inhibitor that acts on the Cholesteryl Ester Transfer Protein (CETP). This compound has demonstrated in clinical studies its capacity to lower low-density lipoprotein cholesterol (LDL-C) and, concurrently, significantly elevate high-density lipoprotein cholesterol (HDL-C). Established in 2019, the company is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$47.86
▲(38.00% Upside)
Technical Analysis
Ownership Overview
6.26% Insiders
22.10% Mutual Funds
20.47% Other Institutional Investors
49.50% Public Companies and
Individual Investors